The pharmaceutical community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s demonstrating significant efficacy in clinical trials for treating obesity. Unlike some existing weight loss treatments, retatrutide appears to provide a greater substantial loss in body weight and enhance metabolic function, pa